Literature DB >> 17990984

Enzyme substrate recognition in oxygen sensing: how the HIF trap snaps.

Eric Metzen1.   

Abstract

The transcriptional activator HIF (hypoxia-inducible factor) is a focal point of biomedical research because many situations in physiology and in pathology coincide with hypoxia. The effects of HIF activation may be a facet of normal growth, as in embryonic development, they may counterbalance a disease, as seen in the stimulation of erythropoiesis in anaemia, and they may be part of the pathological processes, as exemplified by tumour angiogenesis. The oxygen-sensitive alpha-subunits of HIF are primarily regulated by the enzymatic hydroxylation that induces rapid proteasomal degradation. The HIFalpha hydroxylases belong to a superfamily of dioxygenases that require the co-substrates oxygen and 2-oxoglutarate as well as the cofactors Fe2+ and ascorbate. The regulation of enzyme turnover by the concentration of the cosubstrate oxygen constitutes the interface between tissue oxygen level and the activity of HIF. The HIFalpha prolyl hydroxylases, termed PHDs/EGLNs (prolyl hydroxylase domain proteins/EGL nine homologues), bind to a conserved Leu-Xaa-Xaa-Leu-Ala-Pro motif present in all substrates identified so far. This recognition motif is present twice in HIF1alpha, which gives rise to a NODD [N-terminal ODD (oxygen-dependent degradation domain)] containing Pro402 of HIF1alpha and a CODD (C-terminal ODD) where Pro564 is hydroxylated. PHD1/EGLN2 and PHD2/EGLN1 hydroxylate both ODDs with higher activity towards CODD, whereas PHD3/EGLN3 is specific for CODD. The reason for this behaviour has been unclear. In this issue of the Biochemical Journal, Villar and colleagues demonstrate that distinct PHD/EGLN domains, that are remote from the catalytic site, function in substrate discrimination. This elegant study improves our understanding of the interaction of the oxygen-sensing PHDs/EGLNs with their substrates, which include, but are not limited to, the HIFalpha proteins.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17990984      PMCID: PMC2267343          DOI: 10.1042/BJ20071306

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  10 in total

1.  Prolyl hydroxylase-1 negatively regulates IkappaB kinase-beta, giving insight into hypoxia-induced NFkappaB activity.

Authors:  Eoin P Cummins; Edurne Berra; Katrina M Comerford; Amandine Ginouves; Kathleen T Fitzgerald; Fergal Seeballuck; Catherine Godson; Jens E Nielsen; Paul Moynagh; Jacques Pouyssegur; Cormac T Taylor
Journal:  Proc Natl Acad Sci U S A       Date:  2006-11-17       Impact factor: 11.205

Review 2.  Hydroxylation of hypoxia-inducible transcription factors and chemical compounds targeting the HIF-alpha hydroxylases.

Authors:  K Bruegge; W Jelkmann; E Metzen
Journal:  Curr Med Chem       Date:  2007       Impact factor: 4.530

3.  C. elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation.

Authors:  A C Epstein; J M Gleadle; L A McNeill; K S Hewitson; J O'Rourke; D R Mole; M Mukherji; E Metzen; M I Wilson; A Dhanda; Y M Tian; N Masson; D L Hamilton; P Jaakkola; R Barstead; J Hodgkin; P H Maxwell; C W Pugh; C J Schofield; P J Ratcliffe
Journal:  Cell       Date:  2001-10-05       Impact factor: 41.582

4.  von Hippel-Lindau protein binds hyperphosphorylated large subunit of RNA polymerase II through a proline hydroxylation motif and targets it for ubiquitination.

Authors:  Anna V Kuznetsova; Jaroslaw Meller; Phillip O Schnell; James A Nash; Monika L Ignacak; Yolanda Sanchez; Joan W Conaway; Ronald C Conaway; Maria F Czyzyk-Krzeska
Journal:  Proc Natl Acad Sci U S A       Date:  2003-02-25       Impact factor: 11.205

5.  Cell type-specific, topoisomerase II-dependent inhibition of hypoxia-inducible factor-1alpha protein accumulation by NSC 644221.

Authors:  Mark Creighton-Gutteridge; John H Cardellina; Andrew G Stephen; Annamaria Rapisarda; Badarch Uranchimeg; Karen Hite; William A Denny; Robert H Shoemaker; Giovanni Melillo
Journal:  Clin Cancer Res       Date:  2007-02-01       Impact factor: 12.531

6.  Identification of a region on hypoxia-inducible-factor prolyl 4-hydroxylases that determines their specificity for the oxygen degradation domains.

Authors:  Diego Villar; Alicia Vara-Vega; Manuel O Landázuri; Luis Del Peso
Journal:  Biochem J       Date:  2007-12-01       Impact factor: 3.857

Review 7.  Cancer genes and the pathways they control.

Authors:  Bert Vogelstein; Kenneth W Kinzler
Journal:  Nat Med       Date:  2004-08       Impact factor: 53.440

8.  Inhibitory PAS domain protein (IPAS) is a hypoxia-inducible splicing variant of the hypoxia-inducible factor-3alpha locus.

Authors:  Yuichi Makino; Arvydas Kanopka; William J Wilson; Hirotoshi Tanaka; Lorenz Poellinger
Journal:  J Biol Chem       Date:  2002-07-15       Impact factor: 5.157

9.  Cellular oxygen sensing: Crystal structure of hypoxia-inducible factor prolyl hydroxylase (PHD2).

Authors:  Michael A McDonough; Vivian Li; Emily Flashman; Rasheduzzaman Chowdhury; Christopher Mohr; Benoît M R Liénard; James Zondlo; Neil J Oldham; Ian J Clifton; Jeffrey Lewis; Luke A McNeill; Robert J M Kurzeja; Kirsty S Hewitson; Evelyn Yang; Steven Jordan; Rashid S Syed; Christopher J Schofield
Journal:  Proc Natl Acad Sci U S A       Date:  2006-06-16       Impact factor: 11.205

Review 10.  Oxygen sensing by HIF hydroxylases.

Authors:  Christopher J Schofield; Peter J Ratcliffe
Journal:  Nat Rev Mol Cell Biol       Date:  2004-05       Impact factor: 94.444

  10 in total
  4 in total

1.  Genome-wide identification of TAL1's functional targets: insights into its mechanisms of action in primary erythroid cells.

Authors:  Mira T Kassouf; Jim R Hughes; Stephen Taylor; Simon J McGowan; Shamit Soneji; Angela L Green; Paresh Vyas; Catherine Porcher
Journal:  Genome Res       Date:  2010-06-21       Impact factor: 9.043

Review 2.  Vitamin C: update on physiology and pharmacology.

Authors:  J Mandl; A Szarka; G Bánhegyi
Journal:  Br J Pharmacol       Date:  2009-06-05       Impact factor: 8.739

3.  A biology-driven approach identifies the hypoxia gene signature as a predictor of the outcome of neuroblastoma patients.

Authors:  Paolo Fardin; Annalisa Barla; Sofia Mosci; Lorenzo Rosasco; Alessandro Verri; Rogier Versteeg; Huib N Caron; Jan J Molenaar; Ingrid Ora; Alessandra Eva; Maura Puppo; Luigi Varesio
Journal:  Mol Cancer       Date:  2010-07-12       Impact factor: 27.401

4.  DSIR: assessing the design of highly potent siRNA by testing a set of cancer-relevant target genes.

Authors:  Odile Filhol; Delphine Ciais; Christian Lajaunie; Peggy Charbonnier; Nicolas Foveau; Jean-Philippe Vert; Yves Vandenbrouck
Journal:  PLoS One       Date:  2012-10-30       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.